Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259479 · ClinicalTrials.gov registry record · Phase 1
Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors
A Phase 1 study of Solid Tumors and Brain Metastases, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01259479 is a Phase 1 study of Solid Tumors and Brain Metastases that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 9 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01259479, a Phase 1 study of Solid Tumors and Brain Metastases, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Cisplatin and carboplatin are standard cancer treatment drugs used for various childhood cancers, including brain tumors. Both drugs frequently have severe side effects that may reduce their effectiveness, particularly in children, and new treatments are needed that may be similarly effective but less toxic for cancer patients. * Satraplatin is an experimental drug, similar to cisplatin and carboplatin, that has not yet been approved by the Food and Drug Administration. Satraplatin has been shown to treat cancer by interfering with genetic material (DNA) in cancer cells. Some adults with cancer who have received satraplatin had slowing of the growth or shrinkage of their tumor. Researchers are interested in determining whether satraplatin can be effective for cancers that occur in children. Objectives: * To evaluate the safety and effectiveness of satraplatin as a treatment for children and young adults who have solid tumors that have not responded to standard treatment. * To study the effects of satraplatin on the body in terms of side effects and blood chemistry. * To examine the effect that genetic variations may have on the effectiveness of satraplatin. Eligibility: \- Children, adolescents, and young adults between 3 and 21 years of age who have solid tumors (including brain tumors) that have not responded to standard treatment. Design: * Participants will be screened with a full physical examination and medical history, blood tests, and tumor imaging studies. * Participants will receive satraplatin pills to be taken every day in the morning for 5 consecutive days, with no food for 2 hours before or 1 hour after the dose. Participants will then have 23 days without the drug to complete a 28-day cycle of treatment. Participants will also receive medication to prevent nausea and vomiting 30 minutes before the first dose of satraplatin. Following the first dose of satraplatin, medication for nausea will be given if needed. * Satraplatin doses
Conditions Studied
Interventions
- DRUG Satraplatin
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-12-03 |
| Est. Completion | 2015-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259479
The ClinicalTrials.gov registry entry for NCT01259479 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (97% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Satraplatin is the first listed.
NCT01259479 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01259479 about?
NCT01259479 is a clinical study titled "Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors". Background: * Cisplatin and carboplatin are standard cancer treatment drugs used for various childhood cancers, including brain tumors. Both drugs frequently have severe side effects that may reduce their effectiveness, particularly in children, and new treatments are needed that may be similarly e...
What is the current status of trial NCT01259479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-12-03. Estimated completion is 2015-05-29.
What conditions does trial NCT01259479 study?
This clinical trial studies the following conditions: Solid Tumors, Brain Metastases, Brain Tumors.
What interventions are being tested in trial NCT01259479?
The interventions under investigation include: Satraplatin (DRUG).
Who is sponsoring clinical trial NCT01259479?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01259479 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.